Together with trastuzumab deruxtecan and margetuximab, zanidatamab appears to be a good candidate for integration with chemotherapy or immunotherapy in future for HER2 positive gastric cancer patients [5, 6]. The gene discussed is ERBB2; the disease is gastric cancer.